If you have been reading about stoichiometric ratio and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
=== EC 1.18.1 With NAD+ or NADP+ as acceptor === EC 1.18.1.1: rubredoxin—NAD+ reductase EC 1.18.1.2: ferredoxin—NADP+ reductase EC 1.18.1.3: ferredoxin—NAD+ reductase EC 1.18.1.4: rubredoxin—NAD(P)+ reductase EC 1.18.1.5: Putidaredoxin—NAD+ reductase EC 1.18.1.6: adrenodoxin-NADP+ reductase EC 1.18.1.7: ferredoxin—NAD(P)+ reductase (naphthalene dioxygenase ferredoxin-specific) EC 1.18.1.8: Now EC 7.2.1.2, ferredoxin—NAD+ oxidoreductase (Na+-transporting)
Directed by Ben Stiller, the film was a satirical black comedy, in which Carrey played a lonely, menacing cable television installer who infiltrates the life of one of his customers (played by Matthew Broderick). The role was a departure from the "hapless, hyper, overconfident" characters he had been known for. However, it did not fare well with most critics, many reacting to Carrey's change of tone from previous films. Carrey also starred in the music video of the film's closing song, "Leave Me Alone" by Jerry Cantrell. Despite the reviews, The Cable Guy grossed $102 million worldwide. He soon bounced back with the critically acclaimed comedy Liar Liar (1997), playing Fletcher Reede, an unethical lawyer rendered unable to lie by his young son's birthday wish. Carrey was praised for his performance, earning a second Golden Globe Award nomination for Best Actor. Janet Maslin of The New York Times said: "Well into his tumultuous career, Mr. Carrey finally turns up in a straightforward comic vehicle, and the results are much wilder and funnier than this mundane material should have allowed." The following year he decided to take a pay cut to play the seriocomic role of Truman Burbank in the satirical comedy-drama film The Truman Show (1998). The film was highly praised and brought Carrey further international acclaim, leading many to believe he would be nominated for an Academy Award. He won the Golden Globe Award for Best Actor in a Motion Picture Drama but did not receive an Academy Award nomination.
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.
During the lockdown Gavin suggested, 'Why don't we record these things so we've at least got studio recordings of this material?' That doesn't mean we're going to make a new album or it's ever gonna come out, but we have started this process." In a November 2024 interview with Louder Sound, Jakszyk was questioned about the band's future and mentioned the possibility of new studio recordings being released, stating: "The honest answer is, you'll have to ask Robert. It's all in his hands. He's retired a million times before, but he is 78. One of the things we have been doing of late is recording studio versions of the new material [only previously played live]. We've used the live recordings as a template, and I've done guitars, overdubs and backing vocals. Whether that comes out as a King Crimson album or whether it lies in the vaults, I don't know." Eight months later, in a July 2025 interview with Goldmine magazine, Jakszyk stated that "as we speak, we're doing a King Crimson studio album" and confirmed that it featured the most recent band line-up. He cautioned "when that will come out and what format or how — that's beyond my brief. But yeah, we've been doing it piecemeal, and then a couple of months ago, the management said, 'Can we?' So, yeah. I've been recording that with a view to it coming out in some format at some point. But who knows when?... There also are future plans for some live film of us playing in various places. There's an ongoing thread.
May 31: Decree regarding the admission of women to the role of Foreign Trade Advisor. June 14: The issuance of a passport no longer requires a husband's authorization for a married woman. September 30: Decree establishing a Higher Council for Child Protection. 1938
Sources: en.wikipedia.org
In August, the Federal Police (PF) launched Operations Carbono Oculto, Quasar and Tank against a multibillion-real scheme of fraud in the fuel sector and money laundering, revealing that the First Capital Command (PCC) and companies in the financial market used fintechs and transactions via PIX to move and conceal large sums. According to the investigation, the absence of oversight, intensified by the disinformation that circulated on social media about the new Federal Revenue Service oversight rule that would be implemented at the beginning of the year but was revoked due to fake news, facilitated the criminal group's activity. Later, deputies requested the investigation of Nikolas over the video in which he criticized the new oversight of financial movements via Pix."These fake news were so strong that, despite all the effort of the Federal Revenue Service, we could not overcome these lies, because of the strength of those who boosted them. [...] And today's operations show who gained from these lies, from these fake news". — Robinson Barreirinhas, special secretary of the Federal Revenue Service.
=== Duchenne muscular dystrophy === Several morpholino oligos have been approved to treat specific groups of mutations causing Duchenne muscular dystrophy. In September 2016, eteplirsen (ExonDys51) received FDA approval for the treatment of cases that can benefit from skipping exon 51 of the dystrophin transcript. In December 2019, golodirsen (Vyondys 53) received FDA approval for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript. In August 2020, viltolarsen (Viltepso) received FDA approval for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript.
=== Filming === Scouting began in the beginning of July. The table read for the first episode was announced to occur on July 14, 2015, by Kerry Washington. The title of the season premiere, "Heavy is the Head" was revealed on August 8, 2015, by its director Tom Verica on Twitter. Filming for the season began on July 16, 2015. Several actors working on ShondaLand-produced shows directed an episode for the fifth season. Tony Goldwyn from Scandal directed the second and 17th episodes, making it the fourth and fifth episodes he has directed on the show. Chandra Wilson, who plays Dr. Miranda Bailey on Grey's Anatomy, directed her first Scandal episode, which was the sixth episode "Get Out of Jail, Free". Scott Foley from Scandal also directed his first Scandal episode, the 16th named "The Miseducation of Susan Ross". Foley's director-debut was announced on Twitter by Foley himself and executive producer Tom Verica.
Anchoring fibrils composed of type VII collagen extend from the basal lamina into the underlying reticular lamina and loop around collagen bundles. Although found beneath all basal laminae, they are especially numerous in stratified squamous cells of the skin. These layers should not be confused with the lamina propria, which is found outside the basal lamina.
An agent harness, or agent scaffold, is the software layer surrounding a large language model that enables it to function as an AI agent. It commonly manages prompts, context, tool use, memory, execution state, operational constraints, sandboxes, permissions, and the processing of results. The harness connects the model to internal and external computer hardware, software, data files, databases, web browsers, command-line interfaces, and application programming interfaces, while controlling how the agent accesses and uses these resources to complete multi-step tasks.
Sources: en.wikipedia.org
=== Entrepreneurship and biotechnology investing === Springer co-founded biotechnology companies Scholar Rock in 2012, Morphic Therapeutic in 2015, Tectonic Therapeutic in 2019, and Seismic Therapeutic in 2022. He was also an early investor in Selecta Biosciences and Editas Medicine. Springer was a founding investor of Moderna after investing USD$5 million in 2010. He was the company's fourth-largest shareholder and made USD$400 million when the company launched its initial public offering (IPO) in 2018. During the COVID-19 pandemic, Forbes estimated Springer's net worth as USD$1 billion after in share price of biotechnology companies surged.
The intense research for development of efficient chiral selectors has resulted in the synthesis of over 1400 CSPs and over 200 CSPs have been commercialized and available in the market. The most commonly employed chiral selectors are categorized and presented in the table. It is surprising to note that In 1980, there was no single chiral stationary phase available in the market for performing chiral chromatography. However, In late 1980s the subject of enantioselective chromatography attracted growing interest, particularly under the drive of the institution of Okamoto in Japan, the teams of Pirkle, and Armstrong in the US, Schurig and König in Germany, Lindner in Austria, and Francotte in Switzerland . The Polysaccharides, amylose and cellulose, form the most abundant chiral polymers on earth. These naturally occurring polysaccharides form basis for an important class of chiral selectors.
== Precautions == Californium that bioaccumulates in skeletal tissue releases radiation that disrupts the body's ability to form red blood cells. The element plays no natural biological role in any organism due to its intense radioactivity and low concentration in the environment. Californium can enter the body from ingesting contaminated food or drinks or by breathing air with suspended particles of the element. Once in the body, only 0.05% of the californium will reach the bloodstream. About 65% of that californium will be deposited in the skeleton, 25% in the liver, and the rest in other organs, or excreted, mainly in urine. Half of the californium deposited in the skeleton and liver are gone in 50 and 20 years, respectively. Californium in the skeleton adheres to bone surfaces before slowly migrating throughout the bone. The element is most dangerous if taken into the body. In addition, californium-249 and californium-251 can cause tissue damage externally, through gamma ray emission. Ionizing radiation emitted by californium on bone and in the liver can cause cancer.
==== Electrolyte recycling ==== Electrolyte recycling consists of two phases. The collection phase extracts the electrolyte from the spent Li-ion battery. This can be achieved through mechanical processes, distillation, freezing, solvent extraction, and supercritical fluid extraction. Due to the volatility, flammability, and sensitivity of the electrolyte, the collection process poses a greater difficulty than the collection process for other components of a Li-ion battery. The next phase consists of separation/electrolyte regeneration. Separation consists of isolating the individual components of the electrolyte. This approach is often used for the direct recovery of the Li salts from the organic solvents. In contrast, regeneration of the electrolyte aims to preserve the electrolyte composition by removing impurities which can be achieved through filtration methods. The recycling of the electrolytes, which consists 10–15 wt.% of the Li-ion battery, provides both economic and environmental benefits. These benefits include the recovery of the valuable Li-based salts and the prevention of hazardous compounds, such as volatile organic compounds (VOCs) and carcinogens, being released into the environment. Compared to electrode recycling, less focus is placed on recycling the electrolyte of Li-ion batteries due to lower economic benefits and greater process challenges.
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
Peptide content is usually measured by reverse-phase high-performance liquid chromatography, while copper is measured by atomic spectroscopy. Mass spectrometry can confirm the peptide identity and detect copper adducts. Combining these methods gives a more complete picture.